LSE · GDR.L
Genedrive Plc
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
Loading market information…
LSE · OBD.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 08:06 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Oxford BioDynamics Plc’s quoted price sits in the lower half of its reported 52-week range, 67.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oxford BioDynamics Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
£0.06+£0.00 (+2.65%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
£0.07£0.00 (0.0%)
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
£0.01£0.00 (0.0%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 70.51% below the high.
£0.02£0.00 (0.0%)
Cambridge Nutritional Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 44.64% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00-£0.00 (-12.5%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
